Autolus Therapeutics (AUTL) News Today $2.49 -0.09 (-3.49%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Autolus Therapeutics (NASDAQ:AUTL) Reaches New 1-Year Low - Here's WhyAutolus Therapeutics (NASDAQ:AUTL) Sets New 52-Week Low - Here's What HappenedDecember 13, 2024 | marketbeat.comWellington Management Group LLP Acquires 6,330,392 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Wellington Management Group LLP grew its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 35.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,220,226 shares of the company's stock after buying an addDecember 11, 2024 | marketbeat.comAutolus Therapeutics: Undervalued Potential in ALL Treatment with Obe-celDecember 9, 2024 | markets.businessinsider.comAutolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024December 9, 2024 | globenewswire.comNeedham & Company LLC Reaffirms Buy Rating for Autolus Therapeutics (NASDAQ:AUTL)December 8, 2024 | americanbankingnews.comFmr LLC Acquires 5,478,706 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Fmr LLC boosted its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 44.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,773,873 shares of the company's stock after aDecember 7, 2024 | marketbeat.comPositive Outlook for Autolus Therapeutics Driven by Regulatory Approval and Competitive Positioning in CAR-T TherapyDecember 5, 2024 | markets.businessinsider.comAutolus Therapeutics plc (AUTL): A Bull Case TheoryDecember 5, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Slightly Higher in Wednesday TradingDecember 4, 2024 | msn.comErste Asset Management GmbH Makes New $708,000 Investment in Autolus Therapeutics plc (NASDAQ:AUTL)Erste Asset Management GmbH purchased a new stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 195,000 shares of the company's stock, valued at approxDecember 4, 2024 | marketbeat.comAutolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of MedicineDecember 3, 2024 | markets.businessinsider.comAutolus Therapeutics announces publication of data from FELIX studyDecember 3, 2024 | markets.businessinsider.comGreat Point Partners LLC Has $10.21 Million Position in Autolus Therapeutics plc (NASDAQ:AUTL)Great Point Partners LLC decreased its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 18.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,811,955 shares of the company's stock after sellingNovember 27, 2024 | marketbeat.comGoldman Sachs Upgrades Autolus Therapeutics plc - Depositary Receipt () (AUTL)November 19, 2024 | msn.comAutolus Therapeutics upgraded to Buy from Neutral at Goldman SachsNovember 18, 2024 | markets.businessinsider.comAutolus Therapeutics: FDA Approval of Aucatzyl De-Risks Platform, Significant Upside AnticipatedNovember 18, 2024 | markets.businessinsider.comAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Here's WhyAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - What's Next?November 18, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Upgraded at The Goldman Sachs GroupThe Goldman Sachs Group raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $7.00 to $7.60 in a research report on Monday.November 18, 2024 | marketbeat.com298,086 Shares in Autolus Therapeutics plc (NASDAQ:AUTL) Acquired by GSA Capital Partners LLPGSA Capital Partners LLP bought a new position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 298,086 shares of the company's stock, valued at approximately $1,082,000November 16, 2024 | marketbeat.comRedburn Atlantic Upgrades Autolus Therapeutics plc - Depositary Receipt () (AUTL)November 16, 2024 | msn.comAutolus Therapeutics upgraded to Buy from Neutral at Redburn AtlanticNovember 15, 2024 | markets.businessinsider.comAutolus Therapeutics plc (NASDAQ:AUTL) Short Interest UpdateAutolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 7,190,000 shares, a decrease of 17.8% from the October 15th total of 8,750,000 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is currently 6.4 days.November 15, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Trading Up 4% - Still a Buy?Autolus Therapeutics (NASDAQ:AUTL) Trading 4% Higher - Should You Buy?November 15, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Upgraded to Buy at Redburn AtlanticRedburn Atlantic upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price on the stock in a report on Friday.November 15, 2024 | marketbeat.comEquities Analysts Set Expectations for AUTL FY2024 EarningsAutolus Therapeutics plc (NASDAQ:AUTL - Free Report) - Research analysts at William Blair cut their FY2024 EPS estimates for shares of Autolus Therapeutics in a note issued to investors on Tuesday, November 12th. William Blair analyst M. Phipps now forecasts that the company will post earnings ofNovember 15, 2024 | marketbeat.comAutolus Therapeutics Q3 2024 Financial Update and FDA ApprovalNovember 13, 2024 | markets.businessinsider.comAutolus Therapeutics plc (NASDAQ:AUTL) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comAutolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ...November 13, 2024 | finance.yahoo.comAutolus Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 13, 2024 | finance.yahoo.comAutolus Therapeutics Wins FDA Approval for AUCATZYL®November 13, 2024 | markets.businessinsider.comAutolus Therapeutics plc 2024 Q3 - Results - Earnings Call PresentationNovember 12, 2024 | seekingalpha.comWhat To Expect From Autolus Therapeutics PLC (AUTL) Q3 2024 EarningsNovember 11, 2024 | finance.yahoo.comAutolus Therapeutics' (AUTL) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $9.00 price objective on shares of Autolus Therapeutics in a report on Monday.November 11, 2024 | marketbeat.comAutolus Therapeutics Gets FDA Approval for Cancer TreatmentNovember 9, 2024 | marketwatch.comPositive Outlook for Autolus Therapeutics Amid Upcoming PDUFA Review and CAR-T AdvancementsNovember 9, 2024 | markets.businessinsider.comAutolus wins FDA approval of Aucatzyl for acute lymphoblastic leukemiaNovember 9, 2024 | msn.comAutolus Therapeutics announces FDA approval of AucatzylNovember 9, 2024 | markets.businessinsider.comAutolus Therapeutics (NASDAQ:AUTL) Trading Down 10.1% - Time to Sell?Autolus Therapeutics (NASDAQ:AUTL) Shares Down 10.1% - Here's What HappenedNovember 8, 2024 | marketbeat.comAutolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)November 8, 2024 | globenewswire.comAutolus Therapeutics to present clinical data updates at ASH 2024November 6, 2024 | markets.businessinsider.comAutolus Therapeutics (AUTL) to Release Earnings on TuesdayAutolus Therapeutics (NASDAQ:AUTL) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=641167)November 5, 2024 | marketbeat.comFurther weakness as Autolus Therapeutics (NASDAQ:AUTL) drops 21% this week, taking five-year losses to 71%November 3, 2024 | finance.yahoo.comAutolus Therapeutics (NASDAQ:AUTL) Shares Down 4.6% - What's Next?Autolus Therapeutics (NASDAQ:AUTL) Trading Down 4.6% - Time to Sell?October 30, 2024 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Sees Large Drop in Short InterestAutolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 8,750,000 shares, a drop of 13.3% from the September 30th total of 10,090,000 shares. Based on an average trading volume of 801,900 shares, the days-to-cover ratio is presently 10.9 days.October 29, 2024 | marketbeat.comAutolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024October 28, 2024 | globenewswire.comSG Americas Securities LLC Sells 121,911 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)SG Americas Securities LLC decreased its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 64.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 67,329 shares of the company's stock after selling 121,911October 22, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Shares Down 5% - Should You Sell?Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 5% - Here's WhyOctober 21, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - What's Next?Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Should You Buy?October 18, 2024 | marketbeat.comAutolus Therapeutics (AUTL): High-Growth UK Stock in Cancer TherapyOctober 18, 2024 | msn.comAutolus Therapeutics (NASDAQ:AUTL) Sees Large Volume Increase - Here's WhyAutolus Therapeutics (NASDAQ:AUTL) Sees Unusually-High Trading Volume - Here's WhyOctober 17, 2024 | marketbeat.com Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address AI Crypto Tool Could Send One Coin SOARING… (Ad)The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto project Discover our #1 crypto pick before it's too late. AUTL Media Mentions By Week AUTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUTL News Sentiment▼0.710.72▲Average Medical News Sentiment AUTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUTL Articles This Week▼24▲AUTL Articles Average Week Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bausch Health Companies News Today Arrowhead Pharmaceuticals News Today Dyne Therapeutics News Today Catalyst Pharmaceuticals News Today HUTCHMED News Today Agios Pharmaceuticals News Today Protagonist Therapeutics News Today Iovance Biotherapeutics News Today Amneal Pharmaceuticals News Today Longboard Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AUTL) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AUTL Stock Alerts